

February 23, 2007

ASTELLAS AND BOEHRINGER WON THE LAWSUIT AGAINST FLOMAX[®] GENERIC FOR PATENT INFRINGEMENT IN THE USA

Astellas Pharma Inc. (headquarters: Tokyo; President and CEO: Masafumi Nogimori; “Astellas”) and Boehringer Ingelheim Pharmaceuticals, Inc. (“BIPI”), a US subsidiary of Boehringer Ingelheim of Germany, have jointly filed a patent infringement lawsuit in the United States against “Ranbaxy” regarding its submission of an abbreviated new drug application (ANDA) for a generic version of Astellas’ product, sold under the trademark Flomax[®] (generic name: tamsulosin HCl; brand name in Japan: Harnal[®]), which is used for the treatment of benign prostatic hyperplasia. The patent infringement action was filed at the US Federal District Court in New Jersey on May 13, 2005 requesting, among others, an order that date of approval of Ranbaxy’s ANDA be not earlier than the expiration on October 27, 2009 of Astellas’ US Patent No. 4,703,063 on tamsulosin HCl, or any later date of exclusivity Astellas and BIPI are or become entitled.

Astellas today announced that the case was decided in favor of the plaintiffs by the District Court on February 21, 2007 (US Eastern Standard Time).

Tamsulosin HCl was invented by Astellas and has been marketed in 66 countries since it was launched in Japan in 1993. In the US, under a license from Astellas, BIPI has been marketing the product since 1997 under the brand name of Flomax[®]. Since October 2004, Astellas Pharma US, Inc., a US subsidiary of Astellas, has been copromoting the product with BIPI.

Astellas intends to enforce their intellectual property rights against any further infringement.

#####

Contacts for inquiries or additional information
Astellas Pharma Inc. Corporate Communications Tel: +81-3-3244-3201 Fax: +81-3-5201-7473 http://www.astellas.com